Evidence map›Paper›PMID 33463473›Full record

ReviewCurrent neuropharmacology2021

Non-canonical Molecular Targets for Novel Analgesics: Intracellular Calcium and HCN Channels.

Daniel C Cook, Peter A Goldstein

Open access · greenAbstract readReview
In one paragraph

Review in Current neuropharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. IThe Journal of physiology · 2023
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Daniel C CookDepartment of Anesthesiology, Weill Cornell Medicine, New York, NY 10065, United States.
Peter A GoldsteinDepartment of Anesthesiology, Weill Cornell Medicine, New York, NY 10065, United States.
Cornell University · US

Funding

Novel HCN1-selective small molecule inhibitors for the treatment of neuropathic painUG3NS114947 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI GOLDSTEIN, PETER A · 2019 to 2019
$1.8M
NINDS NIH HHS UG3 NS114947
6 · The paper itself

Abstract

Pain is a prevalent biopsychosocial condition that poses a significant challenge to healthcare providers, contributes substantially to a disability, and is a major economic burden worldwide. An overreliance on opioid analgesics, which primarily target the μ-opioid receptor, has caused devastating morbidity and mortality in the form of misuse and overdose-related death. Thus, novel analgesic medications are needed that can effectively treat pain and provide an alternative to opioids. A variety of cellular ion channels contribute to nociception, the response of the sensory nervous system to a noxious stimulus that commonly leads to pain. Ion channels involved in nociception may provide a suitable target for pharmacologic modulation to achieve pain relief. This narrative review summarizes the evidence for two ion channels that merit consideration as targets for non-opioid pain medications: ryanodine receptors (RyRs), which are intracellular calcium channels, and hyperpolarization-activated cyclic nucleotide-gated (HCN) channels, which belong to the superfamily of voltage-gated K+ channels. The role of these channels in nociception and neuropathic pain is discussed and suitability as targets for novel analgesics and antihyperalgesics is considered.

Indexed as

CalciumNeuralgiaAnalgesicsHumansHyperpolarization-Activated Cyclic Nucleotide-Gated ChannelsAnalgesicsCalciumHyperpolarization-Activated Cyclic Nucleotide-Gated Channelsanalgesicantihyperalgesic.drug developmentHCNNeuropathic painryanodine receptor

Identifiers

PMID33463473
PMCPMC9185781
OpenAlexW3121326576

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.